Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.


Glideslope AI-powered market news
No market stories in the last 7 days. The latest coverage is below.

No scored stories in the last 7 days.
| Day | Mood | Stories |
|---|---|---|
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
| Fri, Oct 2 | — | 0 |
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

Novo Nordisk announced an update to the Singapore label for semaglutide, approved in Singapore as Wegovy® (semaglutide) injection, incorporating clinical evide…
Novo Nordisk and Vivani Medical are collaborating to evaluate a semaglutide drug implant using Vivani's NanoPortal platform for chronic weight management. Viva…
Dr. Reddy's Laboratories Limited (NYSE:RDY) on Friday launched its generic Semaglutide Injection in Canada. This move is significant as it positions Dr. Reddy'…

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.
Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE